Randomized, Phase II Study of Pembrolizumab (MK-3475) versus Chemotherapy in Patients with Advanced Melanoma (KEYNOTE 002)
Latest Information Update: 12 May 2022
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Dacarbazine; Paclitaxel; Temozolomide
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms KEYNOTE-002
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 01 Apr 2021 Results comparing tumor best overall response by RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab and data was obtained from this trial published in the European Radiology
- 23 Dec 2020 Results (n=1567) of landmark analysis assessing the long-term safety of pembrolizumab monotherapy across KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 published in the European Journal of Cancer
- 21 Sep 2020 Results (n=1567) of pooled analysis from KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 evaluating long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome in advanced melanoma, presented at the 45th European Society for Medical Oncology Congress